AXL-TBK1 driven AKT3 activation promotes metastasis
Science Signaling · 17.12.2024 · 17 (867)
DOI: 10.1126/scisignal.ado6057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, erschienen am 17.12.2024. Verfasst von Emily N Arner und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Graduate Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Axl Receptor Tyrosine Kinase, Epithelial-Mesenchymal Transition, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
The receptor tyrosine kinase AXL promotes tumor progression, metastasis, and therapy resistance through the induction of epithelial-mesenchymal transition (EMT). Here, we found that activation of AXL resulted in the phosphorylation of TANK-binding kinase 1 (TBK1) and the downstream activation of AKT3 and Snail, a transcription factor critical for EMT. Mechanistically, we showed that TBK1 directly bound to and phosphorylated AKT3 in a manner dependent on the multiprotein complex mTORC1. Upon activation, AKT3 interacted with and promoted the nuclear accumulation of Snail, which led to increased EMT as assessed by marker abundance. In human pancreatic ductal adenocarcinoma tissue, nuclear AKT3 colocalized with Snail and correlated with worse clinical outcomes. Primary mouse pancreatic cancer cells deficient in AKT3 showed reduced metastatic spread in vivo, suggesting selective AKT3 inhibition as a potential therapeutic avenue for targeting EMT in aggressive cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Biology Graduate Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Department of Surgery and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
- BerGenBio ASA, Bergen, Norway.
- Regional Institute of Oncology, Iasi, Romania.
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
ORCID-Profile: Emily N Arner, Jill M Westcott, Stefan Hinz, Natalie Phinney, Vidal Fey, David Micklem, Johanna Ivaska, Rolf A Brekken
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Arner, E. N., Alzhanova, D., Westcott, J. M., Hinz, S., Tiron, C. E., Blø, M., Mai, A., Virtakoivu, R., Phinney, N., Nord, S., Aguilera, K. Y., Rizvi, A., Toombs, J. E., Reese, T. C., Fey, V., Micklem, D., Gausdal, G., Ivaska, J., Lorens, J. B., & Brekken, R. A. (2024). AXL-TBK1 driven AKT3 activation promotes metastasis. Science Signaling, 17(867). https://doi.org/10.1126/scisignal.ado6057
Vancouver
Arner EN, Alzhanova D, Westcott JM, Hinz S, Tiron CE, Blø M, et al. AXL-TBK1 driven AKT3 activation promotes metastasis. Science Signaling. 2024;17(867). doi:10.1126/scisignal.ado6057
BibTeX
@article{Arner2024,
author = {Arner, Emily N and Alzhanova, Dina and Westcott, Jill M and Hinz, Stefan and Tiron, Crina Elena and Blø, Magnus and Mai, Anja and Virtakoivu, Reetta and Phinney, Natalie and Nord, Silje and Aguilera, Kristina Y and Rizvi, Ali and Toombs, Jason E and Reese, Tanner C and Fey, Vidal and Micklem, David and Gausdal, Gro and Ivaska, Johanna and Lorens, James B and Brekken, Rolf A},
title = {AXL-TBK1 driven AKT3 activation promotes metastasis},
journal = {Science Signaling},
year = {2024},
volume = {17},
number = {867},
doi = {10.1126/scisignal.ado6057}
}
EUVIMED